Comment

The classic story is a family sitting at home. Someone suggests driving to dinner. Nobody really wants to go, but each person thinks the others do, so everyone agrees. After an exhausting trip, they discover that everyone would have preferred to stay home. Sound familiar?

Mélanie Chamaux, General Manager of Servier Australia and New Zealand, described the listing as the result of a collective effort involving

Simon Dawson, General Manager, Kyowa Kirin Australia and Head of the APAC Cluster covering Australia, Korea and Taiwan, said the listing would provide an important option for eligible patients.

“As the first new therapy to be reimbursed on the PBS for R/R FL in nine years, we are extremely proud to have partnered with Incyte to bring Minjuvi to Australia,” said Carlo Montagner, ST Chief Executive Officer.

The events in the US this week surrounding a former public health leader raise some important questions in Australia about the accountability of 'independent experts'. Why we can't afford to muck up the AI opportunity as new evidence on its use emerges globally. Ongoing debate over access to medicines and the impact of global pricing.

A unique three‑way collaboration announced in Sydney seeks to build a practical blueprint for how Australia can confront a growing dementia crisis, with a particular focus on Alzheimer’s disease.

Medicines Australia and the Generic and Biosimilar Medicines Association are understood to be maintaining their opposition to non-disclosure deeds as a condition of new agreement negotiations.

Over six years, AUScelerate’s first Targeted Translation Research Accelerator program quietly reshaped the landscape for heart and diabetes care in Australia, unlocking $220 million in investment and propelling dozens of new treatments, technologies and support services closer to patients.

CSL has announced it will begin clinical trials to evaluate the safety and efficacy of immunoglobulin produced with its next-generation Horizon 2 manufacturing process.

AusBiotech has launched a new membership category in its 40th year, AusBiotech Connect, designed specifically for companies in their first two years of operation.

It will terrify some to imagine an even larger HTA industrial complex. Yet AI has the potential to fundamentally change its character and make it far more affordable and accessible for more organisations and people. It can open up an institutional framework that is about as accessible as an exclusive golf club.

Professor Trent Munro, General Manager of the BRIJ, and Rebekah Cassidy, CEO of AusBiotech, spoke with BioPharmaDispatch-BPDInsights about the precinct’s contribution to how Australia’s life sciences sector is moving from scientific promise to commercial impact.